Showing a still image. Turn on hardware acceleration in your browser to rotate the 3D body.
Ivim Peptide Library: the peptides Ivim offers, mapped to where they act
18 peptides and medications offered by Ivim, from FDA-approved medicines to compounded peptides launching soon.
Brain & sleep 2
Peptides that act on the brain and nerves: sleep, mood, focus, pain and rare neurodevelopmental disorders.
EpitalonEpithalon, AEDG, Ala-Glu-Asp-Gly Synthetic pineal tetrapeptide
A four-amino-acid peptide based on a compound found in the pineal gland, promoted for sleep and anti-aging. Evidence comes mostly from one Russian research group and lab studies.
Offered by Ivim as a compounded medication. Compounded medications are not FDA-approved and have not been reviewed by the FDA for safety, effectiveness or quality.
Formulations available through Ivim
| Form | Type | Strength |
|---|---|---|
| Injectable | Sterile | 10 mg/mL |
| Injectable | Sterile | 20 mg/mL |
Compounded by licensed partner pharmacies. Your Ivim clinician decides whether any formulation and dose is right for you.
How it works
Epitalon is a synthetic peptide based on a compound found in the pineal gland. Early studies suggest it may influence melatonin production, telomere maintenance, and cellular aging, but its exact mechanism remains unclear.
What the research shows
| Type of evidence | What it shows |
|---|---|
| Small human studies | In 75 women, 20 days of sublingual epitalon raised a urinary melatonin marker about 1.6-fold versus placebo. |
| Animal and lab studies | Cell studies, including lymphocytes from older adults, report telomere and chromatin changes; not shown to extend human lifespan. |
Safety
Human safety is not established. A 2025 review notes missing data on toxicity, genotoxicity, cancer risk and drug interactions. Avoid in pregnancy, breastfeeding and active cancer.
SemaxACTH(4-10) analog, Met-Glu-His-Phe-Pro-Gly-Pro Synthetic ACTH-fragment heptapeptide
A peptide taken nasally based on a fragment of the stress hormone ACTH, used in Russia for stroke and cognitive health. Human evidence is limited to small Russian studies.
Offered by Ivim as a compounded medication. Compounded medications are not FDA-approved and have not been reviewed by the FDA for safety, effectiveness or quality.
How it works
Semax is a fragment of ACTH (amino acids 4-7) with a Pro-Gly-Pro tail for stability. It does not act as a stress hormone. In rat stroke models it raised activity of genes for brain growth factors and altered immune and vascular gene expression.
What the research shows
| Type of evidence | What it shows |
|---|---|
| Small human studies | Russian clinical studies in ischemic stroke patients tested semax with rehabilitation, tracking blood BDNF and motor recovery; not large blinded trials. |
| Animal and lab studies | After cerebral ischemia in rats, semax activated transcription of neurotrophin genes and their receptors. |
Safety
Human safety is not well established outside small Russian studies. Long-term effects are unknown. Avoid in pregnancy and breastfeeding.
Skin & aging 2
Pigment, wound repair, itch and the signal peptides in skin care. Many here are cosmetic ingredients, not drugs.
GHK-CuCopper tripeptide-1, Copper peptide, GHK copper, Glycyl-L-histidyl-L-lysine copper Copper-binding tripeptide (naturally occurring)
A small copper-carrying peptide found naturally in blood. Small, short studies of topical creams show modest skin improvements, and lab studies suggest it may help skin repair.
Available at Ivim as Cu Skin and Cu Hair, non-prescription-strength topical GHK-Cu products for skin and hair. They are not prescription medications and are not FDA-approved drugs.
Available at Ivim
Non-prescription-strength topical products. Not FDA-approved drugs.
How it works
GHK binds to copper, helping regulate its availability in tissues. Laboratory studies suggest that GHK-Cu stimulates fibroblasts to produce collagen, elastin, and glycosaminoglycans while supporting tissue repair and reducing inflammatory and oxidative stress responses.
What the research shows
| Type of evidence | What it shows |
|---|---|
| Small human studies | In about 20 women, one month of thigh cream raised collagen in 70%, vs 50% with vitamin C and 40% with retinoic acid. |
| Small human studies | 12-week facial cream studies (41 to 71 women) reported less fine lines and greater skin density, mostly in non-peer-reviewed reports. |
| Animal and lab studies | Lab and animal work shows wound healing and gene-expression effects; injectable human trials are lacking. |
Safety
Topical use is generally well tolerated; skin irritation can occur. Avoid with copper metabolism disorders (such as Wilson disease), pregnancy or breastfeeding.
GlutathioneGSH, L-glutathione, Reduced glutathione Tripeptide antioxidant (glutamate-cysteine-glycine)
Glutathione is an antioxidant naturally produced by the body that helps protect cells from damage and supports normal detoxification processes. It is available as a supplement and through injections or IV treatments. Small studies suggest possible skin-brightening effects, but benefits are modest or uncertain, particularly with IV use.
Launching soon at Ivim as a compounded medication. Not yet available. Compounded medications are not FDA-approved and have not been reviewed by the FDA for safety, effectiveness or quality.
How it works
Glutathione helps protect cells from oxidative damage and supports the recycling of other antioxidants. It may also influence skin pigmentation by reducing melanin production and shifting it toward lighter pigments, although these effects have not been fully established in humans.
What the research shows
| Type of evidence | What it shows |
|---|---|
| Randomized trial | In 57 women over 12 weeks, oral glutathione 250 mg/day did not significantly lower melanin overall vs placebo; some subgroup and wrinkle measures improved. |
Safety
Oral glutathione has generally been well tolerated in small, short-term studies, although temporary elevations in liver enzymes have been reported. Long-term safety and effectiveness for skin lightening remain uncertain.
Digestive & weight 6
GLP-1 and related weight medicines, plus peptides for the gut, liver and hormone-secreting tumors.
OrforglipronFoundayo Oral small-molecule GLP-1 receptor agonist (not a peptide)
A once-daily pill that activates the GLP-1 receptor. It is a small molecule, not a peptide, included for comparison. Weight loss is smaller than with injectable semaglutide or tirzepatide.
Offered by Ivim as FDA-approved Foundayo.
See Orforglipron at Ivim Health
How it works
A non-peptide molecule that activates the GLP-1 receptor, reducing appetite, slowing stomach emptying and enhancing insulin secretion in the presence of elevated blood glucose, with no food or water timing rules.
What the research shows
| Type of evidence | What it shows |
|---|---|
| Large randomized trials | ATTAIN-1 (adults with obesity, without diabetes): mean weight loss of 7.5%, 8.4% and 11.2% on 6, 12 and 36 mg versus 2.1% on placebo at 72 weeks (treatment-regimen estimand). Trial doses are not prescribing instructions; see the Foundayo label for marketed doses. |
Safety
Boxed warning: risk of thyroid C-cell tumors; do not use with a personal or family history of medullary thyroid cancer or MEN 2. Common side effects are nausea, vomiting, diarrhea and constipation. Also see the label for pancreatitis, gallbladder disease and other warnings.
SemaglutideWegovy, Ozempic, Rybelsus, Wegovy pill GLP-1 receptor agonist
A once-weekly injection or daily pill that mimics the gut hormone GLP-1. It is one of the best-studied weight-loss medicines, with large trials showing major weight loss and, in people with heart disease, a 20% lower rate of major cardiovascular events (heart attack, stroke or cardiovascular death combined).
Offered by Ivim as FDA-approved Ozempic, Wegovy and Wegovy pill. When an Ivim clinician determines a compounded preparation is appropriate for a patient, compounded semaglutide may be prescribed. Compounded and FDA-approved medicines are different products; compounded medications are not FDA-approved.
See Semaglutide at Ivim Health
How it works
Activates GLP-1 receptors in the brain, pancreas and gut. This reduces appetite, slows stomach emptying and increases insulin release when blood sugar is high.
What the research shows
| Type of evidence | What it shows |
|---|---|
| Large randomized trials | STEP 1: 1,961 adults without diabetes lost 14.9% of body weight at 68 weeks on 2.4 mg weekly versus 2.4% on placebo. |
| Large randomized trials | SELECT: in 17,604 adults with heart disease and overweight, major cardiovascular events fell 20% (6.5% vs 8.0%; HR 0.80). |
Safety
Boxed warning for thyroid C-cell tumors; avoid with personal or family history of medullary thyroid cancer or MEN2. Nausea, vomiting, diarrhea and constipation are common. Risks include pancreatitis, gallbladder disease and dehydration-related kidney injury. Not for use in pregnancy.
TirzepatideZepbound, Mounjaro Dual GIP and GLP-1 receptor agonist
A once-weekly injection that acts on two gut hormone receptors, GIP and GLP-1. In large trials it produced roughly 15% to 21% average weight loss and improved obstructive sleep apnea.
Offered by Ivim as FDA-approved Zepbound. When an Ivim clinician determines a compounded preparation is appropriate for a patient, compounded tirzepatide may be prescribed. Compounded and FDA-approved medicines are different products; compounded medications are not FDA-approved.
See Tirzepatide at Ivim Health
How it works
Activates both GIP and GLP-1 receptors, reducing appetite and food intake, slowing stomach emptying and improving insulin response to meals.
What the research shows
| Type of evidence | What it shows |
|---|---|
| Large randomized trials | SURMOUNT-1: at 72 weeks, weight fell 15.0%, 19.5% and 20.9% on 5, 10 and 15 mg versus 3.1% on placebo. |
| Large randomized trials | SURMOUNT-OSA: apnea-hypopnea index fell 25 to 29 events per hour versus about 5 on placebo at 52 weeks. |
Safety
Boxed warning for thyroid C-cell tumors; avoid with personal or family history of medullary thyroid cancer or MEN2. GI side effects are common. Risks include pancreatitis, gallbladder disease and dehydration. May reduce oral contraceptive effectiveness. Not for use in pregnancy.
BPC-157Body Protection Compound-157, Bepecin, PL 14736 Synthetic gastric pentadecapeptide (research peptide)
BPC-157 is a synthetic peptide based on a protein found in stomach fluid. It is being studied for gut health and tissue repair, but evidence comes mainly from animal and laboratory studies, with very limited human research.
Offered by Ivim as a compounded medication. Compounded medications are not FDA-approved and have not been reviewed by the FDA for safety, effectiveness or quality.
Formulations available through Ivim
| Form | Type | Strength |
|---|---|---|
| Injectable | Sterile | 2.5 mg/mL |
| Injectable | Sterile | 3 mg/mL |
| Capsule | Non-sterile | 500 mcg |
Compounded by licensed partner pharmacies. Your Ivim clinician decides whether any formulation and dose is right for you.
How it works
Proposed, mostly from animal work: promotes new blood vessel growth, interacts with nitric oxide signaling, and supports tendon, gut lining and wound repair. How it works in people is not established.
What the research shows
| Type of evidence | What it shows |
|---|---|
| Animal and lab studies | Systematic review found 36 eligible studies, 35 preclinical, reporting tendon, ligament, muscle and gut healing in animals. |
| Small human studies | Only one clinical study qualified: a retrospective series of 12 knee-pain patients, 7 reporting relief over 6 months; no randomized trials. |
Safety
Human safety is not established: no clinical safety data and a half-life under 30 minutes. Theoretical concern about promoting blood vessel growth in cancer. Avoid in pregnancy and competitive sport.
KPVLys-Pro-Val, alpha-MSH (11-13) Alpha-MSH-derived tripeptide (research peptide)
KPV is a three-amino-acid peptide derived from the anti-inflammatory hormone alpha-MSH. Animal studies suggest it may reduce gut and skin inflammation, but its effectiveness in humans remains unproven.
Offered by Ivim as a compounded medication. Compounded medications are not FDA-approved and have not been reviewed by the FDA for safety, effectiveness or quality.
How it works
Lab and animal studies suggest KPV enters intestinal cells and reduces inflammation by blocking inflammatory signals. Its effects appear to occur independently of melanocortin receptors.
What the research shows
| Type of evidence | What it shows |
|---|---|
| Animal and lab studies | Oral KPV taken up via PepT1 reduced inflammation in mouse colitis models. |
| Animal and lab studies | KPV lowered inflammation severity in murine models of inflammatory bowel disease. |
Safety
Human safety is not established. No published human trials. FDA advisers noted unclear formulation, absorption, allergenicity and immunogenicity data. Purity of unregulated products is uncertain.
Lipotropic (MIC) injectionMIC + B12, Lipo-B, Lipo shot, Methionine, inositol and choline Compounded mix of an amino acid, inositol and choline, often with vitamin B12; not a peptide
A compounded injection combining methionine, inositol and choline, usually with B12. These nutrients play roles in liver fat handling, but there are no controlled trials showing the injection causes weight loss.
Offered by Ivim as a compounded medication. Compounded medications are not FDA-approved and have not been reviewed by the FDA for safety, effectiveness or quality.
See Lipotropic (MIC) injection at Ivim Health
How it works
Choline and methionine supply methyl groups and support making phosphatidylcholine, which the liver needs to export fat; deficiency causes fatty liver in animals and people. Inositol is a cell-signaling molecule. Whether injecting them in people who are not deficient changes fat loss is unproven.
What the research shows
| Type of evidence | What it shows |
|---|---|
| No controlled human trials | No randomized trials of MIC or lipotropic injections for weight loss were found; marketing claims rest on the nutrients’ biological roles. |
Safety
Human safety of the injected combination is not well studied. Possible injection-site reactions, stomach upset, and the B12 warnings (rare allergy). Not a substitute for proven weight-loss treatment. Avoid during pregnancy unless a clinician advises it.
Hormones & metabolism 6
Insulin, growth hormone and the pituitary and adrenal signals that set metabolism.
Estradiol17-beta estradiol, Estrace, Climara, Vivelle-Dot, Divigel, Estradiol valerate, Estradiol cypionate, Estradiol patch, gel, cream, injection Steroid hormone (estrogen), not a peptide
The main estrogen made by the ovaries, used to treat menopausal hot flashes, vaginal dryness and bone loss. It works well for symptoms; risks depend on age, dose, route and whether a progestogen is added.
Offered by Ivim in several forms, including a patch and a hypospray. Some forms are compounded. Compounded medications are not FDA-approved and have not been reviewed by the FDA for safety, effectiveness or quality.
How it works
Binds estrogen receptors alpha and beta in many tissues, restoring estrogen signaling that falls after menopause. This steadies temperature control, supports healthy vaginal tissue and slows bone breakdown.
What the research shows
| Type of evidence | What it shows |
|---|---|
| Large randomized trials | In the Women’s Health Initiative (women 50-79, conjugated estrogens plus medroxyprogesterone), risks of breast cancer, stroke, blood clots and heart events rose while fractures fell. |
| Regulatory review | In 2025 FDA asked to remove heart, breast cancer and dementia language from menopausal hormone boxed warnings, keeping endometrial cancer for systemic estrogen-alone products. |
Safety
Boxed warning (systemic estrogen alone): endometrial cancer risk if a uterus is present without a progestogen. Labels still describe WHI risks of clots, stroke and breast cancer. Avoid with breast cancer, past blood clots (deep vein thrombosis/pulmonary embolism), stroke, liver disease or unexplained vaginal bleeding.
SermorelinGeref, GRF 1-29 GHRH analog (first 29 amino acids of GHRH)
A synthetic version of growth hormone-releasing hormone (GHRH) that stimulates the body’s natural production of growth hormone. Ivim offers compounded sermorelin, which is not FDA-approved; the reference product, Geref, was once approved for children with growth hormone deficiency. Evidence for adult anti-aging or body composition use is limited.
Offered by Ivim as a compounded medication. Compounded medications are not FDA-approved and have not been reviewed by the FDA for safety, effectiveness or quality.
How it works
Binds GHRH receptors on the pituitary to stimulate the body’s own growth hormone release, keeping normal feedback controls in place.
What the research shows
| Type of evidence | What it shows |
|---|---|
| Regulatory review | FDA determined in 2013 that Geref was not withdrawn from sale for reasons of safety or effectiveness. |
| Small human studies | Studies in children supported its original approval; adult studies are small and short. |
Safety
Injection-site reactions, flushing, headache and dizziness. Long-term safety for adult wellness use is not established. Avoid with active cancer, untreated hypothyroidism, or pregnancy.
TestosteroneTestosterone cypionate, Testosterone enanthate, AndroGel, Xyosted, TRT, Testosterone replacement therapy Steroid hormone (androgen), not a peptide
The main male sex hormone, prescribed to men with confirmed low testosterone and symptoms. In women it is used off-label, mainly for low sexual desire after menopause; no US product is approved for women.
Launching soon at Ivim for men’s and women’s hormone health, in states where Ivim can prescribe it. Compounded forms are not FDA-approved, and no testosterone product is FDA-approved for women in the US.
How it works
Binds androgen receptors directly and after conversion to DHT, and is partly converted to estradiol. Replacing it restores androgen effects on libido, red blood cell production, muscle and bone.
What the research shows
| Type of evidence | What it shows |
|---|---|
| Large randomized trials | TRAVERSE (5,246 men, high cardiovascular risk, gel vs placebo): major cardiac events 7.0% vs 7.3%, noninferior; more atrial fibrillation, acute kidney injury and pulmonary embolism. |
| Consensus of randomized trials | In postmenopausal women, testosterone improved sexual desire and function in hypoactive sexual desire disorder; evidence does not support other uses. |
Safety
Boxed warning on gels: children exposed to skin contact can be virilized. Can raise blood pressure and hematocrit, suppress sperm and fertility, and increase clot risk. Requires routine lab monitoring. Avoid in pregnancy and with breast or prostate cancer. Women: acne, hair growth, voice change.
EnclomipheneEnclomiphene citrate, Androxal (investigational name), trans-clomiphene Selective estrogen receptor modulator (small molecule, not a peptide)
An oral drug, one of the two isomers in clomiphene, that raises the body’s own testosterone in men with secondary hypogonadism. Trials showed hormone changes, but FDA did not approve it.
Offered by Ivim as a compounded medication. Compounded medications are not FDA-approved and have not been reviewed by the FDA for safety, effectiveness or quality.
See Enclomiphene at Ivim Health
How it works
Blocks estrogen receptors in the hypothalamus and pituitary, removing estrogen’s negative feedback. The pituitary releases more LH and FSH, which stimulates the testes to make more testosterone and sperm.
What the research shows
| Type of evidence | What it shows |
|---|---|
| Randomized trial | In overweight men with secondary hypogonadism, enclomiphene restored testosterone to normal by 16 weeks and maintained sperm concentration, while topical testosterone gel lowered sperm counts. |
| Regulatory review | FDA said its phase 3 design no longer adequately showed clinical benefit (symptoms, not just hormone levels) and asked for more trials; none led to approval. |
Safety
Long-term human safety is not established. Possible effects include headache, hot flashes, mood changes, visual disturbances (reported with clomiphene) and higher estradiol or blood counts. Not studied in women or for fertility outcomes. Requires lab monitoring.
MOTS-cMitochondrial open reading frame of the 12S rRNA-c Mitochondrial-derived peptide
MOTS-c is a peptide produced by mitochondria that may improve insulin sensitivity and exercise performance. Animal studies show promising results, but its effectiveness in humans remains unproven.
Offered by Ivim as a compounded medication. Compounded medications are not FDA-approved and have not been reviewed by the FDA for safety, effectiveness or quality.
Formulations available through Ivim
| Form | Type | Strength |
|---|---|---|
| Injectable | Sterile | 8 mg/mL |
| Injectable | Sterile | 10 mg/mL |
Compounded by licensed partner pharmacies. Your Ivim clinician decides whether any formulation and dose is right for you.
How it works
MOTS-c is a mitochondrial peptide that may help regulate energy use by activating AMPK, a key regulator of metabolism. It may also help cells adapt to stress by influencing gene activity.
What the research shows
| Type of evidence | What it shows |
|---|---|
| Animal and lab studies | In mice, MOTS-c reduced diet-induced obesity and insulin resistance and improved physical performance in older animals. |
Safety
Human safety is not established. Avoid in pregnancy.
NAD+Nicotinamide adenine dinucleotide, NAD, NAD+ IV, NAD+ injection Coenzyme (nucleotide) made from vitamin B3; not a peptide
NAD+ is a molecule that helps cells produce energy and maintain healthy function. Levels may decline with age, but there is limited human evidence that NAD+ injections or IV treatments improve energy, weight management, or aging.
Offered by Ivim as a compounded medication. Compounded medications are not FDA-approved and have not been reviewed by the FDA for safety, effectiveness or quality.
How it works
NAD+ helps cells produce energy, repair DNA, and maintain healthy function. Varying formulations of supplements can increase NAD+ levels in the blood, but it remains unclear how effectively injected NAD+ enters cells.
What the research shows
| Type of evidence | What it shows |
|---|---|
| Small randomized trial | In 30 healthy middle-aged and older adults, oral nicotinamide riboside raised blood NAD+ and was well tolerated; cardiovascular effects were only suggestive. |
| Small randomized trial | In postmenopausal women with prediabetes, 10 weeks of oral NMN increased muscle insulin sensitivity versus placebo. |
| Human studies | Controlled trials of injected or IV NAD+ itself for energy, aging or weight loss are lacking. |
Safety
Long-term safety of injected or IV NAD+ is not established. Oral precursors were well tolerated in short trials. Compounded products vary in quality. Not studied in pregnancy.
Sexual & reproductive 2
Fertility, hormone-sensitive cancers, labor and sexual desire.
PT-141 (Bremelanotide)Bremelanotide, Vyleesi, PT 141 Melanocortin receptor agonist (cyclic peptide)
Ivim offers compounded PT-141, which is not FDA-approved. The FDA-approved version, Vyleesi, is an on-demand injection for low sexual desire causing distress in premenopausal women; in Vyleesi’s trials it modestly raised desire and lowered distress versus placebo, and nausea was common.
Offered by Ivim as compounded PT-141. The FDA-approved version is Vyleesi, an injection approved only for low sexual desire in premenopausal women; Ivim’s compounded PT-141 is a different product. Compounded medications are not FDA-approved and have not been reviewed by the FDA for safety, effectiveness or quality.
See PT-141 (Bremelanotide) at Ivim Health
How it works
Activates melanocortin receptors, mainly MC4R, in brain pathways involved in sexual desire. It is injected under the skin at least 45 minutes before anticipated sexual activity. The exact way this improves desire is not fully understood.
What the research shows
| Type of evidence | What it shows |
|---|---|
| Large randomized trials | Vyleesi: two 24-week phase 3 RECONNECT trials (1,267 premenopausal women) found small but significant gains in desire score and reduced distress versus placebo. |
| Large randomized trials | Vyleesi: nausea, flushing and headache were more frequent than placebo; label reports nausea in 40% and about 8% stopping because of it. |
Safety
From the Vyleesi label: avoid with uncontrolled high blood pressure or known heart disease; causes temporary blood pressure rise. Nausea is common. Focal skin darkening in about 1%. No more than one dose per 24 hours or 8 per month. Use effective contraception, and stop if pregnancy occurs. It can slow absorption of some oral medicines; avoid with oral naltrexone. Skin darkening may not go away. Stop if there is no improvement after 8 weeks.
Enclomiphene & TadalafilEnclomiphene/tadalafil compounded combination Combination: selective estrogen receptor modulator plus PDE5 inhibitor (small molecules, not peptides)
A compounded pairing of enclomiphene (to raise natural testosterone) and tadalafil (for erections). Each part has been studied separately, but no trials have tested the combination itself.
Offered by Ivim as a compounded medication. Compounded medications are not FDA-approved and have not been reviewed by the FDA for safety, effectiveness or quality.
See Enclomiphene & Tadalafil at Ivim Health
How it works
Enclomiphene blocks pituitary estrogen feedback so the body makes more LH and testosterone. Tadalafil inhibits PDE5, increasing cGMP and blood flow in the penis, prostate and bladder smooth muscle, and in lung arteries.
What the research shows
| Type of evidence | What it shows |
|---|---|
| Large randomized trials | Tadalafil’s approval for erectile dysfunction and BPH symptoms rests on placebo-controlled trials summarized in the Cialis label. |
| Randomized trial | Enclomiphene alone raised testosterone and preserved sperm counts in hypogonadal men over 16 weeks. |
| No combination trials | No published trials have tested enclomiphene and tadalafil together for safety or benefit. |
Safety
Never combine tadalafil with nitrates or riociguat (dangerous blood pressure drops). Avoid if sex is unsafe due to heart disease. Seek emergency medical care immediately for erections longer than 4 hours or sudden vision or hearing loss. Enclomiphene’s long-term safety is not established.
For informational purposes only
This library is for informational and educational purposes only. It is not medical advice, it is not a medical claim of any kind, and it is not an endorsement by Ivim Health or its providers of any peptide, product, use or outcome.
Compounded medications, including any that Ivim offers, are not FDA-approved. The FDA does not review compounded medications for safety, effectiveness or quality.
Peptides that are not marked “Offered by Ivim” are not sold or marketed by Ivim. Those that are not FDA-approved are not currently available to compound.
Information about FDA-approved medicines is provided for comparison only. Whether any medication is appropriate for you can only be decided by a licensed clinician after an evaluation.